Abstracts

Business, international

Search abstracts:

Novartis, SGX pair up to develop leukemia drugs

Article Abstract:

Novartis AG of Switzerland and SGX Pharmaceuticals Inc. are joining in research of new leukemia drugs, particularly for patients who develop resistance to the blockbuster Gleevec by Novartis AG. Pharmaceutical companies are focussing on developing next-generation medicines that battle treatment-resistant cancers.

Switzerland, Novartis AG, NVTSY

---

AstraZeneca pipeline suffers another blow

Article Abstract:

AstraZeneca PLC of the United Kingdom announced disappointing research results for an atherosclerosis drug in the pipeline. Research for the drug trial suggested the drug may fend off combined stroke and heart attack, however was no better than a pacebo in reducing cardiovascular death risk.

Product development, Research, Drug therapy, Atherosclerosis, Financial report

---

AstraZeneca signs deal with RNAi company: medical giant will invest money to help develop treatments

Article Abstract:

AstraZeneca PLC has signed a research agreement with UK-based Silence Therapeutics PLC for discovering new respiratory disease treatments using Silence's proprietary RNA interference technology. The deal is valued at approximately $402.2 mil.

Pharmaceutical Preparation Manufacturing, Respiratory Preparations, Ethical Cough & Cold Combinations, Respiratory system agents, Respiratory agents

Similar abstracts:

• Abstracts: Novartis seeks approval to use Gleevec in four rare cancers. Sanofi aims to sell obesity drug this year, despite FDA setback
• Abstracts: Small firm statistics: a hotel sector focus. Benchmarking to improve the strategic planning process in the hotel sector
• Abstracts: Actavis proposes deal to acquire Pliva of Croatia. Actavis sweetens offer for Pliva, creating turbulence for Barr bid
• Abstracts: EU wants to regulate cellphone roaming rates. New EU Chief outlines agenda to spur growth. EU regulators suspend review of Microsoft-ContentGuard deal
• Abstracts: Ford buyouts swell, but outlook remains dire: up to 38,000 U.S. workers will take the deal to leave; more cash bleeding is seen

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.